F
Francesca Zimetti
Researcher at University of Parma
Publications - 81
Citations - 2079
Francesca Zimetti is an academic researcher from University of Parma. The author has contributed to research in topics: Cholesterol & Internal medicine. The author has an hindex of 21, co-authored 55 publications receiving 1462 citations.
Papers
More filters
Journal ArticleDOI
Lomitapide affects HDL composition and function
R. Yahya,Elda Favari,Laura Calabresi,Adrie J.M. Verhoeven,Francesca Zimetti,Maria Pia Adorni,Monica Gomaraschi,Maurizio Averna,Angelo B. Cefalù,Franco Bernini,Eric J.G. Sijbrands,Monique T. Mulder,J.E. Roeters van Lennep +12 more
TL;DR: The hypothesis that the anti-atherogenic potential of HDL seems to be unaffected as total CEC did not seem to change consistently is raised as the net effect of lomitapide appears to be beneficial in HoFH patients.
Book ChapterDOI
Lipid trafficking in cardiovascular disease.
TL;DR: This review scrutinizes potentially atherogenic changes in lipid trafficking and assesses the molecular mechanisms behind it and new developments in risk assessment and new targets for the mitigation of residual CVD risk are addressed.
Journal ArticleDOI
PCSK9 Affects Astrocyte Cholesterol Metabolism and Reduces Neuron Cholesterol Supplying In Vitro: Potential Implications in Alzheimer’s Disease
Bianca Papotti,Maria Pia Adorni,Cinzia Marchi,Francesca Zimetti,Nicoletta Ronda,G. Panighel,Maria Giovanna Lupo,Antonietta Vilella,Daniela Giuliani,Nicola Ferri,Franco Bernini +10 more
TL;DR: An interfering effect of PCSK9, in cooperation with Aβ, on brain cholesterol metabolism leading to neuronal cholesterol reduction, a potentially deleterious effect is revealed.
Journal ArticleDOI
Manidipine reduces pro-inflammatory cytokines secretion in human endothelial cells and macrophages
TL;DR: The experiments highlighted the anti-inflammatory properties of Manidipine in either human endothelial cells or macrophages, which may be related to the high lipophilicity and the antioxidant activity of this compound.
Journal ArticleDOI
Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial
Ikaro Breder,Jéssica da Silva Cunha Breder,Isabella Bonilha,Daniel B. Munhoz,Sheila T Kimura Medorima,Daniela C. Oliveira,Helison R. Carmo,Camila Moreira,Anatol Kontush,Francesca Zimetti,Ilaria Zanotti,Luiz F. Carvalho,Wilson Nadruz,Elza Muscelli,Thiago Quinaglia,Andrei C. Sposito,Exceed-Bhs Trial Investigator +16 more
TL;DR: The hypothesis that proprotein convertase subtilisin/kexin 9 inhibitor (PCSK9i) therapy may mitigate endothelial dysfunction in T2DM patients who are on regular treatment by SGLT2-i is supported.